Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up

• Published in: PloS one 2014-05, Vol.9 (5), p.e97482-e97482
• Main Authors: Lee, Frederick J, Amin, Janaki, Carr, Andrew
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Adults; AIDS; AIDS treatment; Anti-Retroviral Agents - therapeutic use; Antiretroviral agents; Antiretroviral drugs; Antiretroviral therapy; Biology and life sciences; Care and treatment; CD4 antigen; CD4 Lymphocyte Count; Design parameters; Effectiveness; Emtricitabine; Follow-Up Studies; Genotype; Guidelines; Health aspects; Highly active antiretroviral therapy; HIV; HIV infections; HIV Infections - drug therapy; HIV-1; Human immunodeficiency virus; Humans; Inhibitors; Integrase; Linear Models; Medical research; Medicine and health sciences; Meta-analysis; Motivation; Multivariate Analysis; Nucleoside analogs; Physical Sciences; Practice Guidelines as Topic; Pretreatment; Regression analysis; Regression models; Research and Analysis Methods; Studies; Systematic review; Tenofovir; Therapy; Treatment Outcome; United States; United States Dept. of Health and Human Services; Viral Load
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0097482

A comprehensive assessment of initial HIV-1 treatment success may inform study design and treatment guidelines. Group-based, systematic review and meta-analysis of initial antiretroviral therapy studies, in adults, of ≥ 48 weeks duration, reported through December 31, 2012. Size-weighted, intention-to-treat efficacy was calculated. Parameters of study design/eligibility, participant and treatment characteristics were abstracted. Multivariable, random effects, linear regression models with backwards, stepwise selection were then used to identify variables associated with efficacy. Antiviral efficacy (undetectable plasma viral load) and premature cessation of therapy. 114 studies were included (216 treatment groups; 40,124 participants; mean CD4 count 248 cells/µL [SD 81]; mean HIV-1 plasma viral load log10 4.9 [SD 0.2]). Mean efficacy across all groups was 60% (SD 16) over a mean 82 weeks' follow-up (SD 38). Efficacy declined over time: 66% (SD 16) at 48 weeks, 60% (SD 16) at 96 weeks, 52% (SD 18) at 144 weeks. The most common reason for treatment cessation was participant decision (11%, SD 6.6). Efficacy was higher with 'Preferred' than 'Alternative' regimens (as defined by 2013 United States antiretroviral guidelines): 75% vs. 65%, respectively, difference 10%; 95%CI 7.6 to 15.4; p